Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers... see more

TSXV:EVMT - Post Discussion

View:
Post by Zibo510 on Feb 10, 2024 7:57am

Last NR

Biodex sales projections have been increased by 7.5%, but desdespite many recent NR's regarding Biodex EVMT has never released any estimates as to projected sales volume of Biodex products.

Biodex was acquired in April 2023 and was expected to add 26 million in yearly revenue. 

Former director Kyle Wilkes left the company and formed VMS to become an exclusive distributor of Biodex products. 

EVMT is just about to launch sales of new Biodex products. 

Although we don't have sales volume projections I have a feeling that we might be about to see a large increase in revenue from Biodex products. 

Q1 2024 financials will give us an indication of what Biodex sales will add to yearly revenue. 

I think 2024 will be a turning point for the value of the this stock. Big time. 
Comment by Zibo510 on Feb 11, 2024 5:40am
Another point of interest in the NR is the Seller's of Biodex as part of the LOI want a release from being restricted to holding a maximum of 500,000 shares.  There is only one reason I  can  see for  requesting this release, they want to acquire more common shares of EVMT. As well as wanting to conconvert their 4.4+ million shares ffrom Class A shares to common shares I ...more  
Comment by Zibo510 on Feb 11, 2024 2:02pm
Should read Seller's of  Simbex LLC not  Biodex 
Comment by TheProphetElijah on Feb 12, 2024 9:39am
Was the extra $26m already being taken into account previous quarters?
Comment by Zibo510 on Feb 12, 2024 11:09am
I believe Biodex was generating 18mil a year prior to the acquisition and 26mil was a projection of anticipated revenue.  I haven't been able to find a breakdown of income from the different divisions at least not in the MD&A  Q4 year end financials should provide a better insight of revenue breakdown. 
Comment by TheProphetElijah on Feb 12, 2024 12:31pm
So potentially another $26m could be added to revenue, plus 7.5% ?
Comment by Zibo510 on Feb 12, 2024 1:57pm
If Biodex was generating 18 million a year prior to being acquired I would assume that would already be included in EVMT,'s current revenue.  The big question is what is management targeting for Biodex yearly revenue?. Is it 26 million which was the projected revenue in April 2023 ?, or higher. Since the 26 million was mentioned in April we have had a new CEO, change in management ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities